secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2022-12-12T23:59:59+00:00
Accession:  0001628280-22-031695
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo Therapeutics presents updated proof-of-concept data for BIVV003 and giroctocogene fitelparvovec at ASH
--------------------------------------------------------------------------------

- BIVV003 in sickle cell disease: 3 of 4 Group 1 patients maintained HbF >30% with no severe VOCs up to 30 months.
- Group 2 Patient 5 achieved HbF 45% and total Hb 12.4 g/dL at week 26 using improved manufacturing.
- Hemophilia A gene therapy: highest dose cohort had zero annualized bleeding rate in first year post-infusion.
- Mean FVIII activity at week 156 was 25.5% of normal in highest dose cohort with no inhibitor development.
- No treatment-related serious adverse events for BIVV003; one grade 3 hypotension event in hemophilia A study resolved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828022031695/0001628280-22-031695-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828022031695/sgmo-20221210.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-031695

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer